Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2018 | New thyroid cancer trials: questioning ablative radioiodine and exploring resensitization

Jonathan Wadsley, MB, BChir, MA, MRCP, FRCR, of Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, discusses the next steps in low risk thyroid cancer research. The ION trial (NCT01398085) is investigating whether radioiodine is necessary for low risk thyroid cancer, while resensitization is being explored for patients with radioiodine refractive disease in the SELIMETRY trial (EudraCT no. 2015-002269-47). This interview was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.